RIGVIR holding company SIA “Latima” has received a grant granted by the Investment and Development Agency of Latvia (LIAA) for the research into personalized medicine.
The finding is granted in accordance with the decision of the selection committee and the funding will be used for the implementation of a new project – “Investigation of the mechanism of RIGVIR immunomodulator in non-specific immune cell lines”. The project is designed as part of a series of studies to explore the effects of the drug on non-specific immune cell lines to determine how it stimulates the immune response.
The development of personalized medicine provides new opportunities for the diagnosis and treatment of many diseases, including cancer. “The work on a threephase study that will assess the therapeutic efficacy of a particular patient, improve the cost-effectiveness of therapy and, thanks to the funding provided by the LIAA and the implementation of the project, will enable them to compete globally, offering a personalized therapeutic approach that is consistent with the latest trends,” informs Kristine Jučkovica, Executive Director of RIGVIR Holding.